acs.jmedchem.7b01562.pdf (2.56 MB)
Novel aryl substituted pyrazoles as small molecule inhibitors of cytochrome P450 CYP121A1: Synthesis and antimycobacterial evaluation
journal contributionposted on 2020-10-20, 15:09 authored by Ismail M Taban, Hosam EAE Elshihawy, Beyza Torun, Benedetta Zucchini, Clare J Williamson, Dania Altuwairigi, Adeline ST Ngu, Kirsty J McLean, Colin W Levy, Sakshi Sood, Leonardo B Marino, Andrew W Munro, Luiz Pedro S de Carvalho, Claire Simons
Three series of biarylpyrazole imidazole and triazoles are described, which vary in the linker between the biaryl pyrazole and imidazole/triazole group. The imidazole and triazole series with the short -CH2- linker displayed promising antimycobacterial activity, with the imidazole-CH2- series (7) showing low MIC values (6.25-25 μg/mL), which was also influenced by lipophilicity. Extending the linker to -C(O)NH(CH2)2- resulted in a loss of antimycobacterial activity. The binding affinity of the compounds with CYP121A1 was determined by UV-visible optical titrations with KD values of 2.63, 35.6, and 290 μM, respectively, for the tightest binding compounds 7e, 8b, and 13d from their respective series. Both binding affinity assays and docking studies of the CYP121A1 inhibitors suggest type II indirect binding through interstitial water molecules, with key binding residues Thr77, Val78, Val82, Val83, Met86, Ser237, Gln385, and Arg386, comparable with the binding interactions observed with fluconazole and the natural substrate dicyclotyrosine.
Antitubercular AgentsBacterial ProteinsBinding SitesCrystallography, X-RayCytochrome P-450 Enzyme InhibitorsCytochrome P-450 Enzyme SystemDrug Evaluation, PreclinicalMicrobial Sensitivity TestsMolecular Docking SimulationMycobacterium tuberculosisPyrazolesSmall Molecule LibrariesSpectrophotometry, UltravioletCarvalho FC001060Medicinal & Biomolecular Chemistry0304 Medicinal and Biomolecular Chemistry1115 Pharmacology and Pharmaceutical Sciences0305 Organic Chemistry